title: Novel oral anticoagulants. Part II: direct thrombin inhibitors.
abstract: The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and could soon be ready to transform the history of coagulation medicine. The first part of this article (published in last month's Expert Review of Hematology) embraced a comprehensive review of oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban, YM150. This second part of the article reviews novel oral direct thrombin inhibitors, such as dabigatran and AZD0837, and a brief description of oral Factor IXa inhibitors, such as TTP889.
authors.affiliation: Department of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. mehtars@upmc.edu
authors.forename: Rohtesh S
authors.initials: RS
authors.lastname: Mehta
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000990:Antithrombin III / Q000378:metabolism*; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D002986:Clinical Trials as Topic; D054796:Drug Dosage Calculations; D015949:Factor IXa / Q000037:antagonists & inhibitors*; D065427:Factor Xa Inhibitors; D006801:Humans; D008875:Middle Aged; D013917:Thrombin / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D065427:Factor Xa Inhibitors; D000990:Antithrombin III; D015949:Factor IXa; D013917:Thrombin